The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression.

Splicing dysregulation is one of the molecular hallmarks of cancer. However, the underlying molecular mechanisms remain poorly defined. Here we report that the splicing factor RBM4 suppresses proliferation and migration of various cancer cells by specifically controlling cancer-related splicing. Particularly, RBM4 regulates Bcl-x splicing to induce apoptosis, and coexpression of Bcl-xL partially reverses the RBM4-mediated tumor suppression. Moreover, RBM4 antagonizes an oncogenic splicing factor, SRSF1, to inhibit mTOR activation. Strikingly, RBM4 expression is decreased dramatically in cancer patients, and the RBM4 level correlates positively with improved survival. In addition to providing mechanistic insights of cancer-related splicing dysregulation, this study establishes RBM4 as a tumor suppressor with therapeutic potential and clinical values as a prognostic factor.

[1]  N. Danial,et al.  BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death , 2007, Clinical Cancer Research.

[2]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[3]  Jung-Chun Lin,et al.  Exon Selection in α-Tropomyosin mRNA Is Regulated by the Antagonistic Action of RBM4 and PTB , 2005, Molecular and Cellular Biology.

[4]  C. Burge,et al.  Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. , 2008, RNA.

[5]  A. Pause,et al.  An oxygen-regulated switch in the protein synthesis machinery , 2012, Nature.

[6]  K. Schulze-Osthoff,et al.  Regulation of apoptosis by alternative pre-mRNA splicing. , 2005, Molecular cell.

[7]  A. Krainer,et al.  S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. , 2013, Cell reports.

[8]  R. Kole,et al.  Anti-tumor activity of splice-switching oligonucleotides , 2010, Nucleic acids research.

[9]  A. Krainer,et al.  THE SPLICING FACTOR SRSF1 REGULATES APOPTOSIS AND PROLIFERATION TO PROMOTE MAMMARY EPITHELIAL CELL TRANSFORMATION , 2011, Nature Structural &Molecular Biology.

[10]  M. Olive,et al.  hnRNP A1 Recruited to an Exon In Vivo Can Function as an Exon Splicing Silencer , 1999, Molecular and Cellular Biology.

[11]  Zefeng Wang,et al.  The splicing activator DAZAP1 integrates splicing control into MEK/Erk regulated cell proliferation and migration , 2014, Nature Communications.

[12]  C. Burge,et al.  A Complex Network of Factors with Overlapping Affinities Repress Splicing through Intronic Elements , 2012, Nature Structural &Molecular Biology.

[13]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[14]  Sherif Abou Elela,et al.  Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing. , 2013, Cancer treatment and research.

[15]  S. Lam,et al.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression , 2012, Genome research.

[16]  Jung-Chun Lin,et al.  RNA-binding Motif Protein 4 Translocates to Cytoplasmic Granules and Suppresses Translation via Argonaute2 during Muscle Cell Differentiation* , 2009, The Journal of Biological Chemistry.

[17]  Premkumar Vummidi Giridhar,et al.  CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches , 2013, Experimental biology and medicine.

[18]  J. Venables.  Unbalanced alternative splicing and its significance in cancer , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  Jung-Chun Lin,et al.  RBM4 Promotes Pancreas Cell Differentiation and Insulin Expression , 2012, Molecular and Cellular Biology.

[20]  Z. Szallasi,et al.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.

[21]  Yi Xing,et al.  An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transition , 2010, The EMBO journal.

[22]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[23]  R. Amann,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2022 .

[24]  C. Bortner,et al.  Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostate and Breast Cancer Cells , 2001, The Journal of Biological Chemistry.

[25]  Wen Chang,et al.  A novel splicing regulator shares a nuclear import pathway with SR proteins , 2003, The EMBO journal.

[26]  Leandro Quadrana,et al.  Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT , 2005, Nature Structural &Molecular Biology.

[27]  Hiroshi Tanaka,et al.  Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell , 2012, Nature Communications.

[28]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[29]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[30]  T. Maniatis,et al.  Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. , 1998, Molecular cell.

[31]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[32]  Jung-Chun Lin,et al.  Exon selection in alpha-tropomyosin mRNA is regulated by the antagonistic action of RBM4 and PTB. , 2005, Molecular and cellular biology.

[33]  Wei Guo,et al.  Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells , 2005, Molecular Cancer Therapeutics.

[34]  Sherif Abou Elela,et al.  Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes , 2008, Molecular Cancer Therapeutics.

[35]  Jane Y. Wu,et al.  RBM4 Interacts with an Intronic Element and Stimulates Tau Exon 10 Inclusion* , 2006, Journal of Biological Chemistry.

[36]  A. Busch,et al.  Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. , 2013, RNA.

[37]  A. Krainer,et al.  The splicing-factor oncoprotein SF2/ASF activates mTORC1 , 2008, Proceedings of the National Academy of Sciences.

[38]  Sherif Abou Elela,et al.  Identification of alternative splicing markers for breast cancer. , 2008, Cancer research.

[39]  S. Dehm.  mRNA splicing variants: exploiting modularity to outwit cancer therapy. , 2013, Cancer research.

[40]  Zefeng Wang,et al.  Intronic Splicing Enhancers, Cognate Splicing Factors and Context Dependent Regulation Rules , 2012, Nature Structural &Molecular Biology.

[41]  C. Ghigna,et al.  Alternative Splicing and Tumor Progression , 2008, Current genomics.

[42]  Anna M. Heidenblut,et al.  Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions , 2005, Oncogene.

[43]  F. Clark,et al.  Understanding alternative splicing: towards a cellular code , 2005, Nature Reviews Molecular Cell Biology.

[44]  Zefeng Wang,et al.  A day in the life of the spliceosome , 2014, Nature Reviews Molecular Cell Biology.

[45]  Yang Wang,et al.  Engineering splicing factors with designed specificities , 2009, Nature Methods.

[46]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[47]  Robert Wechsler-Reya,et al.  BIN1 is a novel MYC–interacting protein with features of a tumour suppressor , 1996, Nature Genetics.

[48]  Jung-Chun Lin,et al.  Cell stress modulates the function of splicing regulatory protein RBM4 in translation control , 2007, Proceedings of the National Academy of Sciences.

[49]  Brian J. Smith,et al.  Structure-guided design of a selective BCL-X(L) inhibitor. , 2013, Nature chemical biology.

[50]  Sherif Abou Elela,et al.  Reprogramming Alternative Pre-messenger RNA Splicing through the Use of Protein-binding Antisense Oligonucleotides* , 2003, Journal of Biological Chemistry.